13 January 2021 - 12:03 By Reuters
Artificial heartmaker Carmat will begin sales of its devices from the second quarter of 2021 after a long-awaited European Commission approval.
Given recurring shortages of donors, Carmat s device aims to give patients with end-stage biventricular heart failure, a deadly condition where the heart is no longer able to pump blood adequately around the body, an alternative to hospital stays.
Carmat s CEO Stephane Piat said: “The idea behind this heart, which was born nearly 30 years ago, was to create a device which would replace heart transplants, a device that works physiologically like a human heart, one that s pulsating, self-regulated and compatible with blood.”